Vaccines based on virus-like nano-particles for use against Middle East Respiratory Syndrome (MERS) coronavirus

Copyright © 2020. Published by Elsevier Ltd..

Recent advances in virus-like nanoparticles against Middle East respiratory syndrome-related coronavirus (MERS-CoV) can initiate vaccine production faster for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), while ensuring the safety, easy administration, and long-term effects. Patients with this viral pathogen suffer from excess mortality. MERS-CoV can spread through bioaerosol transmission from animal or human sources. The appearance of an outbreak in South Korea sparked off a strong urge to design strategies for developing an effective vaccine since the emergence of MERS-CoV in 2012. Well unfortunately, this is an important fact in virus risk management. The studies showed that virus-like nanoparticles (VLPs) could be effective in its goal of stopping the symptoms of MERS-CoV infection. Besides, due to the genetic similarities in the DNA sequencing of SARS-CoV-2 with MERS-CoV and the first identified severe acute respiratory syndrome (SARS-CoV) in China since 2002/2003, strategic approaches could be used to manage SARS-CoV 2. Gathering the vital piece of information obtained so far could lead to a breakthrough in the development of an effective vaccine against SARS-CoV-2, which is prioritized and focussed by the World Health Organization (WHO). This review focuses on the virus-like nanoparticle that got successful results in animal models of MERS-CoV.

Medienart:

E-Artikel

Erscheinungsjahr:

2020

Erschienen:

2020

Enthalten in:

Zur Gesamtaufnahme - volume:38

Enthalten in:

Vaccine - 38(2020), 36 vom: 10. Aug., Seite 5742-5746

Sprache:

Englisch

Beteiligte Personen:

Hashemzadeh, Alireza [VerfasserIn]
Avan, Amir [VerfasserIn]
Ferns, Gordon A [VerfasserIn]
Khazaei, Majid [VerfasserIn]

Links:

Volltext

Themen:

Coronavirus
Journal Article
MERS-CoV
Nanoparticles
Review
Vaccine
Vaccines, Virus-Like Particle
Virus-like particles

Anmerkungen:

Date Completed 11.08.2020

Date Revised 02.03.2023

published: Print-Electronic

Citation Status MEDLINE

doi:

10.1016/j.vaccine.2020.07.003

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM312608098